Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:30 PM
Ignite Modification Date:
2025-12-24 @ 11:30 PM
NCT ID:
NCT00709956
Eligibility Criteria:
Inclusion Criteria:
* Signed informed consent prior to initiation of any study mandated procedure,
* Patients with symptomatic idiopathic, or familial pulmonary arterial hypertension or pulmonary hypertension associated with human immunodeficiency virus (HIV) or drugs/toxins in NYHA functional class II to IV.
* Women of childbearing potential must have a negative urine pregnancy test and must use an adequate method of contraception during the study and for 28 days after discontinuation of the study drug.
Exclusion Criteria:
* Pulmonary arterial hypertension related to any condition other than those specified in the inclusion criteria,
* Pulmonary arterial hypertension associated with significant venous or capillary involvement (Pulmonary capillary wedge pressure (PCWP) \> 15 mmHg),
* Known pulmonary veno-occlusive disease, or pulmonary capillary hemangiomatosis,
* Moderate to severe obstructive lung disease: forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) \< 70% and FEV1 \< 65% of predicted value after bronchodilator administration,
* Moderate to severe restrictive lung disease: total lung capacity (TLC) \< 60% of predicted value,
* Pregnant or breast-feeding women,
* Systemic hypertension (systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg on repeated measurement),
* Systolic blood pressure \< 95 mmHg,
* Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C,
* Chronic renal insufficiency defined by serum creatinine \> 2.5 mg/dL (221 μmol/L) or ongoing dialysis,
* Clinically relevant bleeding disorder or active bleeding,
* For those patients on monotherapy, any contraindication to bosentan, ambrisentan, or sildenafil, according to product label,
* Known hypersensitivity to iloprost or any of its excipients.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00709956
Study Brief:
Protocol Section:
NCT00709956